GLAXO

GLAXOSMITHKLINE PHARMACEUTICALS

Large Cap BSE: 500660 NSE: GLAXO
₹1473.15
-5.4 (-0.37%)
  • Advice
  • Hold
As on 20 August, 2022 | 08:28

Glaxosmithkline Pharmaceuticals Share Price

Glaxosmithkline Pharmaceuticals Performance

Day Range

  • Low
  • High

52 Week Range

  • Low
  • High
  • Open Price
  • Previous Close
  • Volume

Glaxosmithkline Pharmaceuticals Share Returns

  • Over 1 Month -2.6%
  • Over 3 Month -3.39%
  • Over 6 Month -6.03%
  • Over 1 Year -6.48%

Glaxosmithkline Pharmaceuticals Key Statistics

P/E Ratio 14.7
PEG Ratio 0
Market Cap Cr 24,956
Price to Book Ratio 9.4
EPS 99.2
Dividend 6.1
Relative Strength Index 54.16
Money Flow Index 63.03
MACD Signal -15.58
Average True Range 27.48

Glaxosmithkline Pharmaceuticals Investment Rating

  • Master Rating:
  • Glaxosmithkline Pharms. has an operating revenue of Rs. 3,380.52 Cr. on a trailing 12-month basis. An annual revenue growth of 10% is good, Pre-tax margin of 24% is great, ROE of 63% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 200DMA and close to its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 80 which is a GOOD score indicating consistency in earnings, a RS Rating of 29 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 113 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of D is close to being the worst. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

EPS Strength

Price Strength

Buyer Demand

Group Rank

GlaxoSmithKline Pharmaceuticals Financials
  • Indicator
  • Jun 2022
  • Mar 2022
  • Dec 2021
  • Sep 2021
  • Jun 2021
  • Mar 2021
  • Oper Rev Qtr Cr
  • 729
  • 792
  • 808
  • 992
  • 773
  • 807
  • Operating Expenses Qtr Cr
  • 582
  • 619
  • 611
  • 717
  • 623
  • 638
  • Operating Profit Qtr Cr
  • 148
  • 173
  • 197
  • 274
  • 151
  • 169
  • Depreciation Qtr Cr
  • 16
  • 15
  • 18
  • 18
  • 18
  • 18
  • Interest Qtr Cr
  • 1
  • 0
  • 1
  • 0
  • 1
  • 1
  • Tax Qtr Cr
  • 44
  • 262
  • 33
  • 69
  • 44
  • 48
  • Net Profit Qtr Cr
  • 119
  • 1,218
  • 150
  • 203
  • 120
  • 13

Glaxosmithkline Pharmaceuticals Technicals

EMA & SMA

Current Price
1473.15
-5.4 (-0.37%)
  • Bullish Moving Average
  • ___
  • 9
  • Bearish Moving Average
  • ___
  • 7
  • 20 Day
  • 1454.51
  • 50 Day
  • 1478.95
  • 100 Day
  • 1517.71
  • 200 Day
  • 1588.1
  • 20 Day
  • 1444.28
  • 50 Day
  • 1485.49
  • 100 Day
  • 1526.15
  • 200 Day
  • 1589.11

Glaxosmithkline Pharmaceuticals Resistance and Support

PIVOT
₹1474.4
Resistance
  • First Resistance
  • 1491.15
  • Second Resistance
  • 1503.75
  • Third Resistance
  • 1520.5
Support
  • First Resistance
  • 1461.8
  • Second Resistance
  • 1445.05
  • Third Resistance
  • 1432.45
  • RSI
  • 54.16
  • MFI
  • 63.03
  • MACD Single Line
  • -15.58
  • MACD
  • -7.07

Glaxosmithkline Pharmaceuticals Delivery and Volume

  • Period
  • NSE + BSE
    Volume Avg
  • NSE + BSE
    Delivery Volume Avg
  • NSE + BSE
    Delivery Volume %
  • Day
  • 55,565
  • 3,697,851
  • 66.55
  • Week
  • 64,815
  • 4,936,940
  • 76.17
  • 1 Month
  • 81,456
  • 5,538,217
  • 67.99
  • 6 Month
  • 46,844
  • 2,857,460
  • 61

Glaxosmithkline Pharmaceuticals Result Highlights

GlaxoSmithKline Pharmaceuticals Synopsis

NSE-Medical-Diversified

Glaxosmithkline Phar is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 3217.51 Cr. and Equity Capital is Rs. 169.41 Cr. for the Year ended 31/03/2022. GlaxoSmithKline Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 13/11/1924 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24239MH1924PLC001151 and registration number is 001151.
  • Market Cap
  • 24,956
  • Sales
  • 3,321
  • Shares in Float
  • 4.24
  • No of funds
  • 197
  • Yield
  • 2.04
  • Book Value
  • 9.32
  • U/D Vol ratio
  • 1.1
  • LTDebt / Equity
  • Alpha
  • -0.03
  • Beta
  • 0.42

GlaxoSmithKline Pharmaceuticals

  • Owner Name
  • Jun-22
  • Mar-22
  • Dec-21
  • Sep-21
  • Promoters
  • 75%
  • 75%
  • 75%
  • Mutual Funds
  • 4.06%
  • 4.17%
  • 4.18%
  • Foreign Portfolio Investors
  • 2.16%
  • 2.18%
  • 2.04%
  • Financial Institutions/ Banks
  • 0.02%
  • 1.44%
  • 1.43%
  • Individual Investors
  • 10.41%
  • 10.41%
  • 10.66%
  • Others
  • 8.35%
  • 6.8%
  • 6.69%

GlaxoSmithKline Pharmaceuticals Management

  • Name
  • Designation
  • Ms. R S Karnad
  • Chairperson
  • Mr. Sridhar Venkatesh
  • Managing Director
  • Dr.(Ms.) S Maheshwari
  • Director
  • Mr. S Williams
  • Director
  • Mr. P V Bhide
  • Director
  • Mr. N Kaviratne
  • Director
  • Mr. A N Roy
  • Director
  • Mr. D Sundaram
  • Director
  • Mr. M Anand
  • Director
  • Mr. J Chandy
  • Director

Glaxosmithkline Pharmaceuticals Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Glaxosmithkline Pharmaceuticals Corporate Action

  • Date
  • Purpose
  • Remarks
  • 2022-07-25
  • Quarterly Results
  • 2022-05-16
  • Audited Results & Dividend
  • 2022-02-07
  • Quarterly Results
  • 2021-10-29
  • Quarterly Results
  • 2021-07-26
  • Quarterly Results
  • Date
  • Purpose
  • Remarks
  • 2022-07-08
  • FINAL
  • Rs.30.00 per share(300%)Dividend
  • 2022-07-08
  • SPECIAL
  • Rs.60.00 per share(600%)Special Dividend
  • 2021-07-20
  • FINAL
  • Rs.30.00 per share(300%)Dividend

GlaxoSmithKline Pharmaceuticals MF Shareholding

  • Name
  • Amount(cr)
  • ICICI Prudential Bluechip Fund Growth
  • 32525
  • Aditya Birla Sun Life Tax Relief 96 Pyt of Inc Dis cum Cap Wdrl
  • 13738
  • Edelweiss Balanced Advantage Fund Regular Plan Growth
  • 8458
  • SBI Magnum Midcap Fund Regular Growth
  • 7472
  • PGIM India Midcap Opportunities Fund Regular Growth
  • 6023

GlaxoSmithKline Pharmaceuticals FAQs

What is Share Price of GlaxoSmithKline Pharmaceuticals ?

GlaxoSmithKline Pharmaceuticals share price is ₹1473 As on 20 August, 2022 | 08:14

What is the Market Cap of GlaxoSmithKline Pharmaceuticals ?

The Market Cap of GlaxoSmithKline Pharmaceuticals is ₹24956 Cr As on 20 August, 2022 | 08:14

What is the P/E ratio of GlaxoSmithKline Pharmaceuticals ?

The P/E ratio of GlaxoSmithKline Pharmaceuticals is 14.7 As on 20 August, 2022 | 08:14

What is the PB ratio of GlaxoSmithKline Pharmaceuticals ?

The PB ratio of GlaxoSmithKline Pharmaceuticals is 9.4 As on 20 August, 2022 | 08:14

Q1FY23